Daiichi Sankyo Company, Limited (DSKYF)
| Market Cap | 32.43B -21.0% |
| Revenue (ttm) | 13.68B +15.5% |
| Net Income | 1.62B -11.2% |
| EPS | 0.81 -16.0% |
| Shares Out | n/a |
| PE Ratio | 20.06 |
| Forward PE | n/a |
| Dividend | 0.56 (3.15%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 36,555 |
| Open | 18.89 |
| Previous Close | 18.31 |
| Day's Range | 17.76 - 18.89 |
| 52-Week Range | 13.85 - 29.15 |
| Beta | -0.16 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Daiichi Sankyo Company
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injec... [Read more]
Financial Performance
In fiscal year 2026, Daiichi Sankyo Company's revenue was 2.12 trillion, an increase of 12.55% compared to the previous year's 1.89 trillion. Earnings were 279.73 billion, a decrease of -5.42%.
Financial numbers in JPY Financial StatementsNews
Daiichi Sankyo Co Ltd's Dividend Analysis
Daiichi Sankyo Co Ltd's Dividend Analysis
Daiichi, Merck Withdraw U.S. Filing For Lung Cancer Drug Ifinatamab Deruxteca
(RTTNews) - Daiichi Sankyo (4568.TS) and Merck (MRK) on Friday announced that they have voluntarily withdrawn the Biologics License Application (BLA) for Ifinatamab deruxtecan (I-DXd) for adult patien...
Daiichi Sankyo and Merck Withdraw Ifinatamab Deruxtecan BLA; MRK Stock Reacts
Daiichi Sankyo and Merck Withdraw Ifinatamab Deruxtecan BLA; MRK Stock Reacts
Merck, Daiichi Sankyo withdraw US application for lung cancer drug
Merck and Daiichi Sankyo have voluntarily withdrawn their US application seeking accelerated approval for their experimental lung cancer therapy, the drugmakers said on Friday.
Malaysia's IHH's unit appeals Tokyo court's rejection of Daiichi Sankyo damages claim
Malaysia's IHH Healthcare said on Thursday its subsidiary has appealed a Tokyo court's dismissal of its damages claim against Daiichi Sankyo over the unit's acquisition of a stake in India's Fortis ...
Fortis investors flag legal overhang after Delhi HC order
Domestic and foreign institutional investors of Fortis Healthcare (Fortis) have expressed concern that the Delhi High Court’s order seeking a forensic audit of transactions involving its former promot...
AstraZeneca: CHMP Recommends Enhertu For Approval In The EU
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) and Daiichi Sankyo's (4568.T) Enhertu has been recommended for approval in the European Union by CHMP as a monotherapy for the adjuvant treatment o...
Daiichi Sankyo Gets Japan Approval For Enhertu, Datroway In First-Line Metastatic Breast Cancer
(RTTNews) - Daiichi Sankyo Company, Limited (4568.T) announced that Japan's Ministry of Health, Labour and Welfare has approved Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan) f...
AstraZeneca's Enhertu Gets NICE Recommendation For HER2 Low Metastatic Breast Cancer
(RTTNews) - AstraZeneca (AZN) and Daiichi Sankyo (4568.T) announced that Enhertu (trastuzumab deruxtecan) has received a positive recommendation from the National Institute for Health and Care Excelle...
Fortis moves Supreme Court against Delhi High Court order
Fortis Healthcare has appealed to the Supreme Court against a recent Delhi High Court order. The order mandated a forensic audit of Fortis's dealings with IHH Healthcare and RHT Health Trust. This leg...
AstraZeneca's Enhertu Improves PFS By 6 Months In First-Line HER2-Mutant NSCLC; Daiichi Stock Up
(RTTNews) - AstraZeneca PLC (AZN) and Daiichi Sankyo Company (4568.T) reported positive results from the Phase 3 DESTINY-Lung04 trial evaluating Enhertu as first-line treatment for patients with unres...
Malaysia's IHH's unit loses Tokyo court case against Daiichi Sankyo over Fortis deal
Malaysia's IHH Healthcare said on Thursday that a Tokyo court has dismissed its unit's damage claims against Japan's Daiichi Sankyo tied to its 2018 acquisition of a stake in India's Fortis Healthcare...
AstraZeneca And Daiichi Sankyo Gain EU Nod For Enhertu Plus Pertuzumab In HER2+ Breast Cancer
(RTTNews) - AstraZeneca (AZN) and Daiichi Sankyo announced that the European Commission has approved Enhertu in combination with Pertuzumab for the treatment of adult patients with HER2-positive metas...
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dos...
TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
TOKYO--(BUSINESS WIRE)--The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus curre...
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization.
Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has appointed Ken Keller to the newly created role of Chief Commercialization Officer, responsible for accelerating further growth of the company's o...
Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
TOKYO--(BUSINESS WIRE)--Enhertu Showed Statistically Significant & Clinically Meaningful PFS Improvement as First-Line Treatment of Patients with HER2 Mutant Advanced NSCLC.
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK...
Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026. “Daiichi Sankyo delivered strong revenue growth in the fi...
Daiichi Sankyo Company Earnings Call Transcript: Q1 2027
Revenue surged 21% YoY in Q1 FY 2026, driven by ENHERTU and DATROWAY, but operating profit fell due to restructuring costs and inventory valuation losses. FY 2026 guidance was raised on strong U.S. sales and yen depreciation, with ongoing investments in operational excellence.
Daiichi Sankyo Company Quarterly report: Q1 2027
Daiichi Sankyo Company has published its Q1 2027 quarterly earnings report on July 31, 2026.
Daiichi Sankyo Company Slides: Q1 2027
Daiichi Sankyo Company has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 31, 2026.
Trump Plans 100% Tariff on Generic Drugs From 2028
President Donald Trump said generic drug manufacturers will have two years to move production to the US or face a 100% import duty. Bloomberg's Mica Soellner reports on what could come next.
AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports
Drugmakers AstraZeneca and Daiichi Sankyo are nearing an agreement with the UK's pricing regulator for their breast cancer treatment Enhertu, Bloomberg News reported on Wednesday, citing multiple pe...